ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Financials / HQL
FTHY (46) ETO (43) TYG (47) NOAH (56) ⌘ Pro Terminal →

abrdn Life Sciences Investors (HQL) — RQD Stock Rating Cockpit

$17.98 -2.49% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.87

abrdn Life Sciences Investors (HQL) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $473.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HQL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HQL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, abrdn Life Sciences Investors (NYSE: HQL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $17.98 (-2.49% 1D, market cap $473.5M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1097 tracked Financials issuers, HQL ranks #625 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HQL compare to FTHY and ETO in the Financials sector?
▼

Within the Financials sector (Investment Managers), HQL carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FTHY (First Trust High Yield Opportunities 2027 Term Fund) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $479.2M) and ETO (Eaton Vance Tax-Advantage Global Dividend Opp) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $484.8M). Among the 5-stock peer group, NOAH leads on earnings multiple (5.8x) while NOAH leads on capital efficiency (11.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HQL?
▼

For abrdn Life Sciences Investors (HQL), key quantitative strengths include Established market leader in Financials with deep daily trading liquidity and sector rank #625 in Financials, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $17.86 (-0.64%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (11)Whales (8)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$24 Bull$17 Base$14 Bear
📬 FREE HQL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HQL)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY HQL SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($13.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$17.26+3.1% Next Q
Q2 (-2Q)
46
Grade D$17.79+1.2% Next Q
Q3 (-1Q)
48
Grade D$18.00-0.1% Next Q
Current
51
Grade D$17.98-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HQL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HQL currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Financials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.97) and Max Pain ($18.88) forces dealer call-delta covering toward $23.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HQL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HQL Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
52.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE33% OF RANGE
L: $16$17.98H: $23
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on HQL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (55)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

17/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like HQL
  • ✓Established market leader in Financials with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HQL)

  • ✓Walkthrough of HQL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HQL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.47%📐 HORIZONTAL RANGE
2026-11-03O $18.74H $18.74L $17.98C $17.98VOL 86.6K
RES: $25.23SUP: $16.08SMA50: $18.97SMA200: $18.26
$23.13$21.22$19.31$17.40$15.49RES $25.23SUP $16.08$17.982026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HQL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HQL Butterfly Map → + Track HQL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HQL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HQL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HQL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HQL)

Financials Rank #625 of 1097 ⚔️ FTHY vs HQL Full Matrix →

1. Head-to-Head Financials Peer Comparison (HQL vs. FTHY, ETO, TYG, NOAH)

Industry: Investment Managers (79 Tracked Issuers)

Across 1097 tracked Financials securities in the Roarable RQD universe, abrdn Life Sciences Investors (HQL) ranks #625 by composite RQD confidence (51/100, grade D) and #716 by equity capitalization ($473.5M). Within this direct 5-issuer industry benchmark cohort, NOAH leads on earnings valuation at 5.8x trailing P/E, while NOAH leads on capital efficiency and profitability with 11.2% ROIC and — gross margin. NOAH currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with HQL at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HQL ACTIVE
abrdn Life Sciences Investors
D 51/100 — — — -2.49% $473.5M Benchmark Subject
FTHY
First Trust High Yield Opportunities 2027 Term Fund
D 46/100 — — — -0.69% $479.2M /fthy-vs-hql →
ETO
Eaton Vance Tax-Advantage Global Dividend Opp
D- 43/100 — — — +0.47% $484.8M /eto-vs-hql →
TYG
Tortoise Energy Infrastructure Corporation
D 47/100 — — — -3.35% $488.3M /tyg-vs-hql →
NOAH
Noah Holdings Limited
D+ 56/100 5.8x — 11.2% +2.97% $451.3M /noah-vs-hql →

2. HQL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

abrdn Life Sciences Investors (HQL) operates in Investment Managers (Financials) with an equity capitalization of $473.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. HQL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HQL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, abrdn Life Sciences Investors (NYSE: HQL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $17.98 (-2.49% 1D, market cap $473.5M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1097 tracked Financials issuers, HQL ranks #625 in composite RQD confidence.

How does HQL compare to FTHY and ETO in the Financials sector?

Within the Financials sector (Investment Managers), HQL carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FTHY (First Trust High Yield Opportunities 2027 Term Fund) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $479.2M) and ETO (Eaton Vance Tax-Advantage Global Dividend Opp) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $484.8M). Among the 5-stock peer group, NOAH leads on earnings multiple (5.8x) while NOAH leads on capital efficiency (11.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HQL?

For abrdn Life Sciences Investors (HQL), key quantitative strengths include Established market leader in Financials with deep daily trading liquidity and sector rank #625 in Financials, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HQL trading relative to its 50-day, 200-day, and 52-week technical levels?

HQL last traded at $17.98 (-2.49% on volume of 79,354 shares), positioning the stock -5.22% below its 50-day simple moving average ($18.97) and -1.53% below its 200-day simple moving average ($18.26). Across its 52-week range of $15.66 to $22.67, HQL sits at the 33.1% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($16.96 to $19.00).

Direct Sub-Reports: HQL RQD Cockpit HQL 12M Forecast HQL Earnings & Move HQL Dividends & DRIP HQL Insiders & 13F HQL Whale Options HQL Profit Sankey HQL News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ SEC XBRL & RQD VERIFIED

HQL — abrdn Life Sciences Investors: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

abrdn Life Sciences Investors (HQL) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $17.98 (-2.49% 1D, market capitalization $473.5M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Is a NYSE-listed issuer in the Financials sector, operating in the Investment Managers industry..5B. — describes its specific products, client base, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 51/100): Established market leader in Financials with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $15.66 – $22.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source data. Sector context is limited to the Financials / Investment Managers classification. Investors should watch for any future disclosure of counterparties or sector linkages, but no second-order ripples are documented in the provided sources.

  • Key Question #1: Can HQL sustain or expand its — operating margin and — ROIC against Investment Managers peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $22.67 52-week high?
  • Key Question #3: How sensitive is HQL's equity valuation to Financials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HQL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for abrdn Life Sciences Investors (HQL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HQL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HQL Bull vs. Bear Conversation Board — What's Your Call at $17.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HQL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HQL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $23.05 (+25.0%)
📌 Pinned Debate

The forensic balance sheet scores 13 of 20, the strongest RQD pillar, with an Altman Z of 2.5, a Piotroski F-Score of 6/9, and Debt/Equ

Don't sleep on HQL's setup in Financials. The forensic balance sheet scores 13 of 20, the strongest RQD pillar, with an Altman Z of 2.5, a Piotroski F-Score of 6/9, and Debt/Equity of 0.5.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (51/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — HQL's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $14.38 (-22.0%)
Spot @ $18.44

Insider conviction is the weakest pillar at 9 of 20, with a 0% ROIC and 0% FCF yield leaving no measurable cash return to support valua

I respect the product at abrdn Life Sciences Investors, but the stock at $18.44 is a different story. Insider conviction is the weakest pillar at 9 of 20, with a 0% ROIC and 0% FCF yield leaving no measurable cash return to support valuation.. FCF yield is 0.0% and RQD sits at 51/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%